| Texto completo | |
| Autor(es): |
Nadia de Cassia Noronha, N. C.
[1, 2]
;
Mizukami, Amanda
[1]
;
Caliari-Oliveira, Carolina
[3]
;
Cominal, Jucara Gastaldi
[1, 2]
;
Rocha, Jose Lucas M.
[1, 4]
;
Covas, Dimas Tadeu
[1]
;
Swiech, Kamilla
[5, 1]
;
Malmegrim, Kelen C. R.
[1, 6]
Número total de Autores: 8
|
| Afiliação do(s) autor(es): | [1] Univ Sao Paulo, Ribeirao Preto Med Sch, Reg Blood Ctr Ribeirao Preto, Ctr Cell Based Therapy, Ribeirao Preto - Brazil
[2] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Grad Program Biosci & Biotechnol, Ribeirao Preto - Brazil
[3] In Situ Cell Therapy, SUPERA Innovat & Technol Pk, Sao Paulo - Brazil
[4] Univ Sao Paulo, Ribeirao Preto Med Sch, Grad Program Basic & Appl Immunol, Ribeirao Preto - Brazil
[5] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Pharmaceut Sci, Ribeirao Preto - Brazil
[6] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Toxicol & Bromatol Anal, Ave Cafe S-N, BR-14010903 Ribeirao Preto, SP - Brazil
Número total de Afiliações: 6
|
| Tipo de documento: | Artigo de Revisão |
| Fonte: | STEM CELL RESEARCH & THERAPY; v. 10, MAY 2 2019. |
| Citações Web of Science: | 7 |
| Resumo | |
Multipotent mesenchymal stromal cells (MSC) have been widely explored for cell-based therapy of immune-mediated, inflammatory, and degenerative diseases, due to their immunosuppressive, immunomodulatory, and regenerative potentials. Preclinical studies and clinical trials have demonstrated promising therapeutic results although these have been somewhat limited. Aspects such as low in vivo MSC survival in inhospitable disease microenvironments, requirements for ex vivo cell overexpansion prior to infusions, intrinsic differences between MSC and different sources and donors, variability of culturing protocols, and potency assays to evaluate MSC products have been described as limitations in the field. In recent years, priming approaches to empower MSC have been investigated, thereby generating cellular products with improved potential for different clinical applications. Herein, we review the current priming approaches that aim to increase MSC therapeutic efficacy. Priming with cytokines and growth factors, hypoxia, pharmacological drugs, biomaterials, and different culture conditions, as well as other diverse molecules, are revised from current and future perspectives. (AU) | |
| Processo FAPESP: | 13/08135-2 - CTC - Centro de Terapia Celular |
| Beneficiário: | Dimas Tadeu Covas |
| Modalidade de apoio: | Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs |